HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
Abstract Background Epidermal growth factor receptor (EGFR) has emerged as an important therapeutic target. Overexpression of EGFR is frequently observed in hepatocellular carcinoma (HCC) and EGFR activation has been proven to be a potential determinant of primary resistance of HCC cells to sorafeni...
Main Authors: | Natthaporn Sueangoen, Anchalee Tantiwetrueangdet, Ravat Panvichian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Cell & Bioscience |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13578-020-00407-1 |
Similar Items
-
Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01) -
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01) -
A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01) -
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
by: Paola Ulivi, et al.
Published: (2014-12-01)